Here, we report a novel small molecule HHQ16, an optimized derivative of astragaloside IV, which effectively reversed infarction-induced myocardial remodeling and improved cardiac function by directly acting on
K562 cells, which represent primitive hematopoietic cells with the potential for multidirectional differentiation, serve as a model for investigating the effects of AS-IV on HSC [35]. We evaluated K562 cell activity following AS-IV treatment. The results of the CCK-8 assay indicated that AS-IV ...